Two day break in treatment for dialysis patients could be fatal, study finds
- Patients given kidney dialysis three times per week more likely to be admitted to hospital or die after two day break in treatment
- Leading Sheffield kidney researcher awarded fellowship to reduce harm caused by break in dialysis treatment
- Study now aims to improve treatment for patients with chronic kidney disease
Patients who have kidney dialysis three times a week are more likely to be admitted to hospital or die after a two day break, according to a study by a leading kidney researcher at the University of Sheffield.
Dr James Fortheringham from the Sheffield Kidney Institute has found there is a 69 per cent increase in hospital admissions and a 22 per cent increase in deaths after a two day break in three times a week haemodialysis.
To help reduce hospital admissions and boost the survival prospects of kidney dialysis patients, Dr Fotheringham has now been awarded a five year fellowship by the National Institute of Health Research (NIHR) Clinician Scientist Award panel – one of only six researchers to be awarded the fellowship this year.
Building on this study, James will now continue his work to understand and reduce the harm being caused by the two day break.
“I’m trying to identify who it is that is getting admitted to hospital and dying after this two day break and why. Harnessing existing data including the valuable UK Renal Registry I will examine if wider use of some of the care techniques we already use here in the UK can combat the two day break problem,” Dr Fotherigham said.
“Doing more dialysis might tackle the two day break problem, but some of what we have learned from existing clinical trials and observational studies don’t always agree. If more dialysis is needed, I want to know who to give this dialysis to and if they will accept it. My research fellowship is designed to answer these and other questions.”
The initial study, funded by Kidney Research UK, was conducted at the University of Sheffield’s School of Health and Related Research (ScHARR) – one of the largest and most dynamic schools of health research in the UK.
Its findings, together with the NIHR Clinician Scientist award, will help Dr Fotheringham and the continuing collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust to improve treatment for patients with chronic kidney disease.
“In addition to identifying and beginning to understand the two day break problem in haemodialysis, I’m very fortunate that my research has yielded some other important results: The UK Renal Registry is developing a new way of reporting survival following dialysis or kidney transplants based on my work.
“Some of my analyses also helped secure funding for a study to find the optimal setup for kidney units to insert a peritoneal dialysis catheter – a treatment given to patients with severe chronic kidney disease,” James added.
“The University of Sheffield’s ScHARR and The Sheffield Teaching Hospitals NHS Foundation Trust are again collaborating on the UK-Cath study.”
The initial research is published in the journal Kidney International and can be viewed here: http://www.nature.com/ki/journal/v88/n3/abs/ki2015141a.html
Dr Fotheringham conducted the study as part of his PhD at the University of Sheffield, where he initially came to study as an undergraduate in medicine.
The University of Sheffield
With almost 26,000 of the brightest students from around 120 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
In 2014 it was voted number one university in the UK for Student Satisfaction by Times Higher Education and in the last decade has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.
Sheffield has five Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For further information please contact:
Media Relations Assistant
University of Sheffield
0114 222 9852